Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
Novo Nordisk(NVO) stock is priced at $51.92, giving the company a market capitalization of 229.09B. It carries a P/E multiple of 13.99 and pays a dividend yield of 2.6%.
As of 2025-12-23, Novo Nordisk(NVO) stock has fluctuated between $50.49 and $53.20. The current price stands at $51.92, placing the stock +2.8% above today's low and -2.4% off the high.
Novo Nordisk(NVO) shares are trading with a volume of 67.56M, against a daily average of 18.37M.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $93.80 and a 52-week low of $43.08.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $93.80 and a 52-week low of $43.08.
NVO News
Mega-cap tech and AI stocks carried major indexes in thin holiday trading, while healthcare strength after Novo Nordisk’s Wegovy pill approval added selective s...
Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of dia...
On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare. Expand NYSE : NVO Novo Nord...
Analyst ratings
55%
of 33 ratingsMore NVO News
Shares of Big Tech climbed higher, lifting the S&P 500 and the Nasdaq 100. The S&P 500 rose for the fourth-consecutive session, closing at a new all-time high....
The approval of Novo Nordisk's (NYSE:NVO) oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 m...
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill? Quick Read Novo Nordisk ( NVO ) received FDA approval for the first oral...
Eli Lilly and Company (NASDAQ:LLY) shares are trading down on Tuesday as investors weigh the competitive landscape in the pharmaceutical sector. Eli Lilly stock...
Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusi...
Novo Nordisk (NVO) is up 8.1%, or $3.92 to $52.02. Claim 70% Off TipRanks This Holiday Season Published first on TheFly – the ultimate source for real-time, m...
Shares of Eli Lilly (LLY) are down about 1% in early trading on Dec. 23 on news that archrival Novo Nordisk’s (NVO) new weight-loss pill has received regulatory...